Erratum: DUET: A phase 2 study evaluating the efficacy and safety of sparsentan in patients with FSGS (Journal of the American Society of Nephrology (2018) 29 (2745–2754) DOI: 10.1681/ASN.2018010091)

The authors wish to make a correction to Supplemental Table 6: Change in Diuretic Treatment During the Doubleblind Period (Full Analysis Set). The table is not published in the main manuscript and is available in the supplemental material found at: http://jasn.asnjournals.org/lookup/suppl/ doi:10.1681/ASN.2018010091/-/DCSupplemental. The new table is below: (Table presented) The only change is a change in the number of "new or increased" loop diuretics from 1 (2.8%) to 2 (5.6%) which lessens the difference between the two groups. This change does not alter the conclusions from this table and does not impact any of the main findings or conclusions reported in the study.